Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH) and Elevated Low-Density Lipoprotein Cholesterol (LDL-C).

NCT03397121 is registered in ClinicalTrials.gov with The Medicines Company as lead sponsor.

NCT NCT03397121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03397121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH) and Elevated Low-Density Lipoprotein Cholesterol (LDL-C).
Lead sponsor
The Medicines Company
Phase
Phase 3
Overall status
Completed
Start date
November 28, 2017
Completion date
September 17, 2019
Enrollment
482 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

elevated cholesterol, heterozygous familial hypercholesterolemia